P53 and heat shock protein 70 expressions in colorectal adenocarcinoma

Saudi Medical Journal

Volumn 26, Issue 10, 2005, Pages 1602-1606

  Shotar, Ali M ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; HEAT SHOCK PROTEIN 70; PROTEIN P53;

AGE; ARTICLE; CANCER CELL; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER TISSUE; CELL CYCLE; CELL NUCLEUS; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENE OVEREXPRESSION; HEALTH SERVICE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JORDAN; LYMPH NODE; MAJOR CLINICAL STUDY; ONCOGENE; PATHOLOGY; PRIVATE HOSPITAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PUBLIC HOSPITAL; STATISTICAL SIGNIFICANCE; UNIVERSITY;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 29144433454     PISSN: 03795284     EISSN: 03795284     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Tsai JY, Safran H. Status of treatment for advanced gastric carcinoma. Curr Oncol Rep 2003; 5: 210-218.
2. Ries LA, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards B. KSEER Cancer Statistics Review 1973-1996. NIH Pub. No. 97-2789. Bethesda (MD): National Cancer Institute; 1999.
3. Elmasri SH, Boulos PB. Prognosis of colo-rectal carcinoma in Sudan. Trop Geogr Med 1976; 28: 187-190.
4. Ibrahim N, Abdul-Karim F. Colorectal carcinoma in young Lebanese adults. The American University of Beirut, Medical Center experience with 32 patients. Cancer 1980; 85: 816-820.
5. Isbister W. Colorectal cancer below age 40 in the Kingdom of Saudi Arabia. Aust N Z J Surg 1992; 62: 468-472.
6. Soliman AS, Bondy ML, Levin B, Hamza MR, Ismail K, Ismail S, et al. Colorectal cancer in Egyptian patients under 40 years of age. Int J Cancer 1997; 71: 26-30.
7. Steven G. Silverberg M. Principles and practice of surgical pathology and cytology. 3rd ed. Baltimore: Churchill Livingstone; 1997.
8. Kaattela M, Wissing D. Emerging role of heat shock proteins in biology and Medicine. Ann Med 1992; 24: 249-258.
9. Ciocca DR, Oesterreich S, Chamness GS, McGuire WL, Fuqua SAW. Biological and clinical implications of heat shock protein 27000 (HSP27): a review. J Natl Cancer Inst 1993; 85: 1558-1570.
10. Benndorf R, Bielka H. Cellular stress response: stress proteins-physiology and implication for cancer. Recent Results Cancer Res 1997; 143: 129-444.
11. Macario AJ. Heat shock proteins anc molecular chaperones: Implications for pathogenesis, diagnostics and therapeutics. Int J Clin Lab Res 1995; 25: 59-70.
12. Lane D, Modgely C, Hupp T. Tumor suppressor genes and molecular chaperones. Philos Trans R Soc Lod B Biol Sci 1993; 399: 369-372.
13. Sato N. Stress proteins in cancer. Tranpakushitsu Kakusan Koso 1994; 39: 22-2237.
14. Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS. Cancer and the heat shock response. Eur J Cancer 1994; 30: 1884-1891.
15. Conroy S, Latchman D. Do heat shock proteins have a role in breast cancer. Br J Cancer 1996; 74: 717-721.
16. Sun XF, Zhang H, Carstensen J, Jansson A, Nordenskjold B. Heat shock protein 72/73 in relation to cytoplasmic p53 expression and prognosis in colorectal adenocarcinomas. Int J Cancer 1997; 74: 600-604.
17. Ungar DR, Hailat N, Strahler JR, Kuick RD, Brodeur GM, Seeger RC, et al. HSP27 expression in neuroblastoma: correlation with disease stage. J Natl Cancer Inst 1994; 86: 780-784.
18. Strahler JR, Kuick R, Eckerskorn C, Lottspeich F, Richardson BC, Fox DA, et al. Identification of two related markers for common acute lymphoblastic leukemia as heat shock proteins. J Clin Invest 1990; 85: 200-207.
19. Tetu B, Lacasse B, Bouchard HL, Lagace R, Huot J, Landry J. Prognostic influence of HSP-27 expression in malignant fibrous histiocytoma: a clinicopathological and immunohistochemical study. Cancer Res 1992; 52: 2325-2328.
20. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Varakis I. Prognostic significance of HSP-27 in astrocytic brain tumors: an immunohistochemical study. Anticancer Res 1997; 17: 2677-2682.
21. Santarosa M, Favaro D, Quaia M, Galligioni E. Expression of heat shock protein72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997; 33: 873-877.
22. Storm F, Mahvi D, Gilchrist K. HSP27 has not diagnostic or prognostic significance in prostate or bladder cancer. Urology 1993; 42: 379-382.
23. Thomas SA, Brown IL, Hollins GW, Hocken A, Kirk D, King RJ, et al. Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br J Urol 1996; 77: 367-372
24. Guzhova IV, Darieva ZA, Melo AR, Margulis BA. Major stress protein HSP70 interacts with NF-kB regulatory complex in human T-lymphona cells. Cell Stress Chaperones 1997; 2: 132-139.
25. Ciocco D, Stati A, Amprino de Castro M. Colocalization of estrogen and progesterone receptors with an estrogen regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue. Breast Cancer Res Treat 1990; 16: 243-251.
26. Lee CS, Montebello J, Rush M, Georgiou T, Wawryk S, Rode J. Overexpression of heat shock protein (HSP) 70 associated with abnormal p53 expression in cancer of the pancreas. Zentralbl Pathol 1994; 140: 259-264.
27. Kontogeogos G, Stefaneanu L, Kovacs K. Stress- response proteins in human pituitary adenomas. Expression of heat-shock protein 72 (HSP-72). Endocrine 1997; 6: 25-29.
28. Osada T, Sakamoto M, Nishibori H, Iwaya K, Matsuno Y, Muto T, et al. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. J Hepatol 1997; 26: 1266-1273.
29. Blom DJ, De Waard-Siebinga I, Apte RS, Luyten GP, Niederkorn JY, Jager MJ. Effects of hyperthermia on expression of histocompatibility antigens and heat shock protein molecules on three human ocular melanoma cell lines. S Melanoma Res 1997; 7: 103-109.
30. Shivapurkar N, Huang L, Ruggeri B, Swalsky PA, Bakker A, Finkelstein S, et al. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Cancer Lett 1997; 115: 39-46.
31. Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clinical Cancer Res 1996; 2: 1649-1657.
32. Rosai J. Rosai and Ackerman's Surgical Pathology, 9th ed. New York: Churchill Livingstone; 2004.
33. Kim Y, Lee S, Park J, Yoon T, Yang M. An immunohistochemical study of the expression of p53 protein in colon cancer. J Korean Med Sci 1995; 10: 176-182.
34. Cotran RS, Kumar V, Collins T. Pathologic basis of disease. 6th ed. Philadelphia (PA): WB Saunders Company; 1999.
35. Ministry of Health. Jordan Cancer Registry, Cancer Incidence in Jordan (1996). Jordan: Ministry of Health; 1998.
36. Li Z. Priming of T-cells by heat shock proteins, Peptide complexes at the basis of tumor vaccines. Semin Immunol 1997; 9: 315-323.
37. Chouchane L, Ahmed S, Bassouche S, Remadi S. Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997; 8: 1489-1496.
38. McCormick TS, McColl KS, Distelhorst CW. Mouse lymphoma cells distined to undergo apoptosis in response to thapsigargin treatment fail to generate a calcium - mediated grp 78/gr 94 stress response. J Biol Chem 1997; 272: 6087-6092.
39. Stulik J, Bures J, Jandik P, Langr F, Kovarova. H, Macela A. The different expression of Proteins recognized by monoclonal anti-heat shock protein 70 (HSP 70) antibody in human colonic deseases. Electrophoresis 1997; 18: 625-628.
40. Hollstein M, Sidnsky D, Volgestein B. Harrisec p53 mutation in human cancers. Science 1991; 253: 49-53.
41. Shumacher U, Adam E, Feldhaus S, Katoh M, Lane D. Cell differentiation and chemotherapy influence p53, andMdm2 immunoreactivity in human HT29 colon cancer cell grown in acid mice. Cancer Lett 2000; 166: 215-221.
42. Sapwotz W, Holden J, Curtin K. Inverse relationship between microsatellite instability and K-ras and p53 gene alteration in colon cancer. Ant J Pathol 2001; 158: 1517-1524.
43. Shao J, Fujiwara T, Kodowak Y. Overexpression of the wild-type p53 gene inhibits NF-Kappa B activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 2000; 19: 726-736.
44. Sandler B, Smirnoff P, Shani A, Idelerich E. The role of the soluble p53 antigen and its auto-antibodies as markers for diagnosis of colon cancer: a comparative study. Int J Mol Med 1998; 1: 453-457.
45. Attallah A, Elhak N, Nafis W, Tall A, Ezzat F. Detection of p53 protein over expression and DNA plidy analysis in colon cancer. Hepatogastroenterology 1997; 44: 1595-1601.
46. Di Leo A, Messa C, Cavallini A, Linsalta M. Estrogens and Colorectal Cancer. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 1-12.
47. Maehara Y, Oki E, Abe T, Tokunaga E, Shibahara K, Kakeji Y, et al. Overexpression of the Heat Shock Protein HSP70 Family and p53 Protein anc Prognosis for Patients with Gastric Cancer. Oncology 2000; 58: 144-151
48. Johnston L. Colon and Rectal Cancer: A Comprehensive Guide for Patients and Families. 1st ed. Sebastopol (CA): O'Reilly; 1999.